PLoS ONE · 2013 · 32 citations · 20 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceDiagnostic MicrobiologyMicrobial GeneticsAntibiotic ResistanceAntimicrobial Susceptibility TestingBeta-lactam ResistanceCarbapenem ResistanceAnion ExchangeBeta-lactamase Mediated ResistanceCarbapenem AntibioticsCarbapenem-hydrolyzing EnzymesCarbapenemase EnzymesEscherichia ColiNew Delhi Metallo-beta-lactamaseβ-Lactam Antibiotics
New Delhi metallo-β-lactamase (NDM-1) is a new metallo-β-lactamase (MBL) that has recently emerged as a global threat because it confers bacteria with resistance to almost all clinically used β-lactam antibiotics. To determine the molecular basis of this threat, NDM-1 was purified from Escherichia coli TransB (DE3) carrying cloned blaNDM-1 gene by an anion-exchange chromatography step followed by a gel permeation chromatography step. The purified enzyme was stable even in extremely alkaline buffer (pH 11) and reached its highest activity at a low temperature (15°C), which was different from other MBLs. The 50% inhibition concentration of EDTA against NDM-1 was 412 nM, which showed that NDM-1 was more susceptible to EDTA than other MBLs. The effects of zinc on NDM-1 differed between cephem and carbapenem complexes, but inhibition at high Zn(2+) concentration was observed for all of tested β-lactam compounds.
20
Kanimozhi Kumarasamy, Mark A. Toleman, Timothy R. Walsh et al. · The Lancet Infectious Diseases · 2010 · 2.9K citations · Full text
Dongeun Yong, Mark A. Toleman, Christian G. Giske et al. · Antimicrobial Agents and Chemotherapy · 2009 · 2.4K citations · Full text
Dongeun Yong, Mark A. Toleman, Christian G. Giske et al. · 2009 · 622 citations